Critical illness-related cortisol insufficiency is a known entity. However, there are instances where there is a normal serum cortisol level in an unresponsive patient with low GCS, even after thorough investigations to rule out other correctable entities. In patients with lesions in the vicinity of hypothalamus, especially basifrontal contusion and vascular lesions affecting ACOM territory, we propose to see the efficacy of fludrocortisone replacement on such patients.
Introduction
Traumatic brain injury is an important public health issue that requires the expertise of informed neurosurgeons, neurointensivists, and other critical care practitioners [1] . Electrolyte abnormalities are common in patients with head injuries, occurring at least once during the hospital course of 59% of the traumatic coma data bank (TCDB) patients and disturbances in serum sodium level, both hyponatremia and hypernatremia, are among the most common [2] . Meticulous attention should be paid to fluid administration and fluid balance [3] . Serum sodium disturbances frequently occur in neurosurgical and neurologic patients and exacerbate their neurologic and general conditions. The disturbance may manifest as hypernatremia or hyponatremia. Hypernatremia usually occurs in the diabetes insipidus syndrome, whereas hyponatremia develops as a syndrome of inappropriate secretion of antidiuretic hormone (SIADH) or cerebral salt-wasting syndrome (CSWS), and contribute to the high morbidity and mortality rates observed in these patients [4] [5] [6] .
Materials And Methods
We included five patients in our study after ruling out surgically correctable causes as well as dyselectrolytemia. Tab fludrocortisone was prescribed starting with the dose of 0.1 mg bd to a maximum of 0.5 mg bd. Written consents were taken from the patient parties. Patients were monitored for features of dyselectrolytemia as well as pulmonary odema. Time to improvement was assessed in number of days in terms of Glasgow coma scale.
Results

S.NO Diagnosis
Day of initiation of replacement There was improvement with GCS score of at least two (earliest improvement in eye [E] component) within two to three days of the initiation of fludrocortisone replacement therapy. Replacement was done within seven to 10 days of admission after ruling out surgically correctable pathologies or other dyselectrolytemias. All patients had good Glasgow outcome scores (GOS) at one month follow-up.
Case 1
A 32-year-old female, a case of RTA with GCS of 15/15, had bifrontal multiple scattered contusions with no mass effect in the CT scan. She was managed conservatively. On the sixth postoperative day, there was deterioration in the GCS of the patient to E2M4V2. Repeat CT showed perilesional odema. She had normal urine output, normal serum sodium, and cortisol level. She was started on fludrocortisone with 0.1 mg bd. Her GCS improved to E4M5V4 on the third day of initiation of the replacement. She was subsequently referred to the plastic surgery department for the management of a decubitous ulcer in the sacral region. She followed up one month later with a GCS of 15 and GOS of 5.
Case 2
A 60-year-old male presented with sudden onset headache, multiple episodes of vomiting, and altered sensorium of one day's duration. CT scan showed a subarachnoid hemorrhage (SAH) Fisher Grade 4 with ventricular extension. Angiography revealed medially pointing left A1 dominant ACOM aneurysm.
He underwent a left pterional craniotomy and clipping of left A1 dominant ACOM aneurysm and incidental left PCOM aneurysm. Postoperative scan showed left basifrontal contusion with no mass effect. The GCS was persistently E2M5V3. The serum cortisol and electrolytes were within normal range. He was started on fludrocortisones replacement. The GCS improved to E4M5V4 on the second day. The GOS at one month follow-up was 4.
Discussion
Critical illness-related corticosteroid insufficiency (CIRCI) reaches up to 50 to 70% of trauma patients [8] [9] [10] . CIRCI increases systemic inflammation and vasopressive requirement [8, 11] . Hydrocortisone decreases the rate of hospital-acquired pneumonia (HAP) and duration of mechanical ventilation in multiple trauma patients with CIRCI [9] . In a subgroup analysis of the HYPOLYTE (Hydrocortisone Polytraumatise) trial, hydrocortisone appears particularly efficient in multiple trauma patients with traumatic brain injury (TBI) [9] .
Fludrocortisone was proposed in association with hydrocortisone for the treatment of CIRCI in septic patients [12] and is recommended in brain injury patients with spontaneous subarachnoid hemorrhage who experience hyponatremia [13] .
The timing of mineralocorticoid deficiency (MD) onset is important in evaluating the possible mechanism for MD. One proposed cause of MD is enhanced 17α-hydroxylase expression, which is seen after chronic stress in rats and in cultured bovine zona glomerulosa cells chronically exposed to adrenocorticotrophic hormone (ACTH) [14] [15] . In animal studies, mild hemorrhage and hypotension resulted in adrenal necrosis within four hours and was associated with a significant decrease in serum glucocorticoid levels [16] . Hypotension and hypoxia may also contribute to the development of MD through release of reactive oxygen species (ROS), cytokines, and dopamine -all of which inhibit aldosterone synthase [17] [18] [19] . No data regarding fludrocortisones use in TBI patients are available to date.
Conclusions
Replacement with fludrocortisone can have a beneficial effect on the clinical improvement of patients with traumatic and vascular insult surrounding hypothalamus territory who remain unawake with low GCS for a prolonged time (7-10 days) without any evidence of dyselectrolytemia or any surgically correctable lesions, especially for lesions near the third ventricle. It is advisable to rule out hypocortisolism, cerebral salt wasting, SIADH, and surgically corrected mass lesion before initiation of the replacement therapy. Further confirmation can be validated by inclusion of a large number of patients.
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